Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

摘要

Hodgkin lymphoma is considered highly curable, with approximately 70% of patients achieving long-term disease control using ABVD induction chemotherapy (adriamycin, bleomycin, vinblastine, dacarbazine) [1]. The standard management for patients with relapsed/refractory disease is salvage chemotherapy followed by autologous stem cell transplant [2]. Unfortunately, this approach is effective only for about 50% of patients [3,4]. For patients who relapse after autologous stem cell transplant, the prognosis is poor, and treatment options remain largely palliative. Allogeneic stem cell transplant is an option for a subset of patients, but its use is limited by transplant associated morbidities/mortality and lack of long-term disease control [5-7].